Share-based Payment Arrangement, Expense of Mirum Pharmaceuticals, Inc. from 31 Mar 2019 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Mirum Pharmaceuticals, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Mar 2019 to 30 Sep 2025.
  • Mirum Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $18,127,000, a 52% increase year-over-year.
  • Mirum Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $65,649,000, a 46% increase year-over-year.
  • Mirum Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $48,444,000, a 38% increase from 2023.
  • Mirum Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $35,023,000, a 30% increase from 2022.
  • Mirum Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $27,007,000, a 17% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Mirum Pharmaceuticals, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $65,649,000 $18,127,000 +$6,219,000 +52% 01 Jul 2025 30 Sep 2025 10-Q 04 Nov 2025 2025 Q3
Q2 2025 $59,430,000 $18,468,000 +$6,633,000 +56% 01 Apr 2025 30 Jun 2025 10-Q 06 Aug 2025 2025 Q2
Q1 2025 $52,797,000 $15,803,000 +$4,353,000 +38% 01 Jan 2025 31 Mar 2025 10-Q 07 May 2025 2025 Q1
Q4 2024 $48,444,000 $13,251,000 +$3,531,000 +36% 01 Oct 2024 31 Dec 2024 10-K 26 Feb 2025 2024 FY
Q3 2024 $44,913,000 $11,908,000 +$3,523,000 +42% 01 Jul 2024 30 Sep 2024 10-Q 04 Nov 2025 2025 Q3
Q2 2024 $41,390,000 $11,835,000 +$3,478,000 +42% 01 Apr 2024 30 Jun 2024 10-Q 06 Aug 2025 2025 Q2
Q1 2024 $37,912,000 $11,450,000 +$2,889,000 +34% 01 Jan 2024 31 Mar 2024 10-Q 07 May 2025 2025 Q1
Q4 2023 $35,023,000 $9,720,000 +$2,823,000 +41% 01 Oct 2023 31 Dec 2023 10-K 26 Feb 2025 2024 FY
Q3 2023 $32,200,000 $8,385,000 +$1,477,000 +21% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024 2024 Q3
Q2 2023 $30,723,000 $8,357,000 +$1,716,000 +26% 01 Apr 2023 30 Jun 2023 10-Q 07 Aug 2024 2024 Q2
Q1 2023 $29,007,000 $8,561,000 +$2,000,000 +30% 01 Jan 2023 31 Mar 2023 10-Q 08 May 2024 2024 Q1
Q4 2022 $27,007,000 $6,897,000 +$1,404,000 +26% 01 Oct 2022 31 Dec 2022 10-K 26 Feb 2025 2024 FY
Q3 2022 $25,603,000 $6,908,000 -$507,000 -6.8% 01 Jul 2022 30 Sep 2022 10-Q 02 Nov 2023 2023 Q3
Q2 2022 $26,110,000 $6,641,000 +$1,818,000 +38% 01 Apr 2022 30 Jun 2022 10-Q 07 Aug 2023 2023 Q2
Q1 2022 $24,292,000 $6,561,000 +$1,276,000 +24% 01 Jan 2022 31 Mar 2022 10-Q 04 May 2023 2023 Q1
Q4 2021 $23,016,000 $5,493,000 +$1,914,000 +53% 01 Oct 2021 31 Dec 2021 10-K 15 Mar 2024 2023 FY
Q3 2021 $21,102,000 $7,415,000 +$3,987,000 +116% 01 Jul 2021 30 Sep 2021 10-Q 09 Nov 2022 2022 Q3
Q2 2021 $17,115,000 $4,823,000 +$1,849,000 +62% 01 Apr 2021 30 Jun 2021 10-Q 04 Aug 2022 2022 Q2
Q1 2021 $15,266,000 $5,285,000 +$2,712,000 +105% 01 Jan 2021 31 Mar 2021 10-Q 05 May 2022 2022 Q1
Q4 2020 $12,554,000 $3,579,000 +$1,512,000 +73% 01 Oct 2020 31 Dec 2020 10-K 09 Mar 2022 2021 FY
Q3 2020 $11,042,000 $3,428,000 +$1,284,000 +60% 01 Jul 2020 30 Sep 2020 10-Q 15 Nov 2021 2021 Q3
Q2 2020 $9,758,000 $2,974,000 +$1,333,000 +81% 01 Apr 2020 30 Jun 2020 10-Q 05 Aug 2021 2021 Q2
Q1 2020 $8,425,000 $2,573,000 +$2,355,000 +1080% 01 Jan 2020 31 Mar 2020 10-Q 06 May 2021 2021 Q1
Q4 2019 $6,070,000 $2,067,000 01 Oct 2019 31 Dec 2019 10-K 09 Mar 2021 2020 FY
Q3 2019 $2,144,000 01 Jul 2019 30 Sep 2019 10-Q 12 Nov 2020 2020 Q3
Q2 2019 $1,641,000 01 Apr 2019 30 Jun 2019 10-Q 06 Aug 2020 2020 Q2
Q1 2019 $218,000 01 Jan 2019 31 Mar 2019 10-Q 07 May 2020 2020 Q1

Mirum Pharmaceuticals, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $48,444,000 +$13,421,000 +38% 01 Jan 2024 31 Dec 2024 10-K 26 Feb 2025 2024 FY
2023 $35,023,000 +$8,016,000 +30% 01 Jan 2023 31 Dec 2023 10-K 26 Feb 2025 2024 FY
2022 $27,007,000 +$3,991,000 +17% 01 Jan 2022 31 Dec 2022 10-K 26 Feb 2025 2024 FY
2021 $23,016,000 +$10,462,000 +83% 01 Jan 2021 31 Dec 2021 10-K 15 Mar 2024 2023 FY
2020 $12,554,000 +$6,484,000 +107% 01 Jan 2020 31 Dec 2020 10-K 09 Mar 2022 2021 FY
2019 $6,070,000 01 Jan 2019 31 Dec 2019 10-K 09 Mar 2021 2020 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.